Table 3.
Antibody responses of study participants as measured by ELISA MERS-CoV S1 assay
|
Low-dose group (n=12) |
High-dose group (n=11) |
All participants*(n=23) |
Control group (n=6) |
|||||
|---|---|---|---|---|---|---|---|---|
| Geometric mean (95% CI) | Seropositivity | Geometric mean (95% CI) | Seropositivity | Geometric mean (95% CI) | Seropositivity | Geometric mean (95% CI) | Seropositivity | |
| Day 0 | 0·20 (0·16–0·24) | 0 | 0·21 (0·18–0·24) | 0 | 0·20 (0·18–0·23) | 0 | 0·24 (0·16–0·38) | 1 (16%) |
| Day 28 | 0·23 (0·16–0·32) | 1 (8%) | 0·34 (0·26–0·43) | 1 (9%) | 0·28 (0·22–0·34) | 2 (9%) | 0·21 (0·14–0·33) | 0 |
| Day 35 | 0·52 (0·28–0·94) | 6 (50%) | 0·87 (0·65–1·16) | 9 (81%) | 0·66 (0·47–0·93) | 15 (65%) | 0·23 (0·15–0·35) | 0 |
| Day 42 | 0·88 (0·48–1·57) | 8 (67%) | 0·90 (0·70–1·20) | 11 (100%) | 0·89 (0·66–1·21) | 19 (83%) | 0·25 (0·19–0·34) | 0 |
| Day 56 | 0·80 (0·47–1·34) | 8 (67%) | 0·74 (0·57–0·98) | 11 (100%) | 0·77 (0·59–1·02) | 19 (83%) | 0·20 (0·17–1·23) | 0 |
| Day 84 | 0·64 (0·39–1·05) | 8 (67%) | 0·54 (0·41–0·70) | 8 (73%) | 0·56 (0·46–0·76) | 16 (70%) | 0·13 (0·07–0·22) | 0 |
| Day 180† | 0·27 (0·14–0·51) | 3/11 (27%) | 0·18 (0·13–0·26) | 0 | 0·22 (0·15–0·33) | 3/22 (14%) | 0·14 (0·10–0·21) | 0 |
| Day 28–180† | 0·55 (0·44–0·70) | 9 (75%) | 0·63 (0·54–0·73) | 11 (100%) | 0·59 (0·51–0·68) | 20 (87%) | 0·18 (0·16–0·22) | 0 |
Data are n (%) unless otherwise stated. MERS-CoV=Middle East respiratory syndrome coronavirus.
*
Except the control group.
†
One participant in the low-dose group moved the day 180 follow-up visit to day 110.